All studies published in Clinical Gastroenterology and Hepatology are embargoed until 3PM ET of the day they are published as corrected proofs on-line. Studies cannot be publicized as accepted manuscripts or uncorrected proofs.

#### Clinical Gastroenterology and Hepatology 2014;∎:∎-∎

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

1

### Celiac Disease: Ten Things That Every Gastroenterologist Should Know

Amy S. Oxentenko and Joseph A. Murray

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

Q4 There are 10 things that all gastroenterologists should know about celiac disease. The immunoglobulin A tissue transglutaminase is the single best serologic test to use for the detection of celiac disease (CD). CD can be recognized endoscopically, and water immersion enhances villi detection, although a normal endoscopic appearance does not preclude the diagnosis. It is recommended that 4 biopsies be taken from the second part of the duodenum and 2 bulb biopsies be taken at the 9 o'clock and 12 o'clock positions to maximize the sensitivity for histologic confirmation of CD. Consider serologic testing of first-degree relatives, patients with type 1 diabetes mellitus, Down's, Turner's, and Williams' syndromes, as well as those with premature osteoporosis, iron deficiency, abnormal liver biochemistries, and other manifestations of CD. Patients already on a prolonged gluten-free diet (GFD) should be tested for the presence of HLA DQ2 or DQ8, thereby avoiding the need for further evaluation of CD in nonallelic carriers. The basic treatment of CD is a strict, lifelong GFD, enabled by an expert dietitian. Newly diagnosed adults with CD should be assessed for micronutrient deficiencies (iron, B12, folate, zinc, copper), fat soluble vitamin deficiencies (vitamin D), and bone densitometry. All patients diagnosed with CD should have clinical follow-up to ensure response and adherence to a GFD. In those with persistent or relapsing symptoms, the robustness of the original diagnosis should be reviewed, gluten exposure sought, and a systematic evaluation for alternative and associated diseases performed. Evaluate those with refractory disease for malignant transformation.

Q5 Keywords: ∎∎∎.

C eliac disease (CD) is increasingly common and topical for both the general and medical communities; therefore, gastroenterologists will be called on for expertise in this area. How CD is diagnosed has changed over time, and confusion abounds regarding the use and interpretation of diagnostic tests, which are often confounded by adoption of the gluten-free diet (GFD). Herein, we address 10 important things that gastroenterologists need to know about CD, which are based on current evidence and our experience in Mayo Clinic's Celiac Disease Clinic.

# 1. How to Use Serology to Diagnose Celiac Disease

Serologic testing for CD has significantly advanced during the past 2 decades. The long-used anti-gliadin antibodies have been supplanted by serology with better test characteristics.<sup>1</sup> For example, endomysial antibody (EMA), used for more than 20 years, has specificity of 99%,<sup>2</sup> although the sensitivity varies because of the technical issues inherent in direct immunofluorescence. This high specificity keeps EMA in use despite tissue transglutaminase (TTG) being identified as the targeted epitope. EMA is used primarily when discordance exists between other markers and histologic findings<sup>1</sup> or when TTG immunoglobulin (Ig) A antibodies are equivocal.

TTG antibodies come in both IgA-based and IgGbased assays, which are performed with enzyme-linked immunosorbent assay by using human recombinant/ derived proteins. IgA TTG has high sensitivity and specificity of  $\sim 98\%$  and is the endorsed serologic marker for evaluating CD.<sup>3</sup> It is well-known that IgA deficiency affects 2%-3% of CD patients and occurs in 1:131 patients tested for CD<sup>4</sup>; thus, IgA-based assays alone are not always reliable. To avoid missing IgAdeficient CD, a serologic cascade testing starting with serum IgA level can be performed, and if normal, an IgA TTG is adequate; however, if the IgA level is low or absent, IgG-based testing with deamidated gliadin peptide (DGP) and/or TTG could be added/substituted<sup>5</sup> (Figure 1). The accuracy of IgG TTG is poor (30%– 70%) in IgA sufficiency, so this test in isolation should not be used for routine CD screening.<sup>6</sup> However, IgG TTG performs well with known IgA deficiency, with sensitivity and specificity approaching 95%.<sup>2</sup>

Point-of-care finger stick TTG antibody testing has been developed as a rapid screen for CD, and although

Abbreviations used in this paper: CD, celiac disease; DBE, double-balloon endoscopy; DGP, deamidated gliadin peptide; EATL, enteropathy-associated T-cell lymphoma; EMA, endomysial antibody; GFD, gluten-free diet; IDA, iron deficiency anemia; Ig, immunoglobulin; MMA, methylmalonic acid; NRCD, nonresponsive celiac disease; RCD, refractory celiac disease; TTG, tissue transglutaminase; T1DM, type 1 diabetes mellitus; VCE, video capsule endoscopy.

111
112
113
114
115
116

### **ARTICLE IN PRESS**



the specificity was reportedly 100%, the sensitivity was only 82%. It cannot be recommended until sensitivity improves.<sup>7</sup>

The newest serologic marker is the DGP antibody, which comes in both IgA-based and IgG-based assays and is significantly better than anti-gliadin antibody testing.<sup>6</sup> Despite specificity that is close to TTG assays, the sensitivity of either the IgA-based or IgG-based DGP in isolation is lower<sup>8</sup>; however, a combined IgA/IgG DGP panel has accuracy equivalent to IgA-based TTG.<sup>2</sup>

In children older than 2 years, IgA TTG is the preferred test. Serologic markers may have decreased sensitivity in children younger than 2 years. The combination of DGP IgA/IgG with IgA TTG is the recommended strategy.<sup>3</sup>

Should panels of serologic studies for CD be more widely used? The answer is no. The widespread use of panels would not be cost-effective as first-line testing; although it may slightly improve overall sensitivity, it reduces specificity, leading to unnecessary endoscopy.<sup>3</sup>

#### Practical Suggestion

170

171

172

173 IgA-based TTG is the serologic test of choice for eval-174 uating CD in patients consuming a gluten-containing diet.

IgG-based tests are needed in IgA deficiency. The use of celiac cascade testing starting with serum IgA level could direct downstream serology. Equivocal or discrepant serologic tests should be interpreted with caution.

# 2. Can Celiac Disease Be Recognized Endoscopically?

#### Gross Endoscopic Views

There are several well-described endoscopic features of CD, including mucosal fold loss, mosaic pattern, scalloping, nodularity, fissuring, and prominent submucosal vascularity (Figure 2A and B). The sensitivity of endoscopic markers varies (59%-94%), yet the specificity is high (92%-100%).<sup>9,10</sup> The pattern of endoscopic markers may differ between adults and children. A mosaic pattern is found commonly in children, and although the frequency of other endoscopic markers of CD increases with age, the mosaic pattern does not.

#### Water Immersion

Water immersion involves instilling 100-200 mL231water into the duodenum after deflation, takes only 30232

Download English Version:

### https://daneshyari.com/en/article/3281343

Download Persian Version:

https://daneshyari.com/article/3281343

Daneshyari.com